Eli Lilly (NYSE:LLY) stock rose 13% overnight after it beat analyst estimates and raised guidance. The company’s GLP-1 drugs for diabetes and weight loss, Zepbound and Mounjaro, propelled the results.The company reported net income of $2.97 billion,$3.28 per share fully diluted, on revenue of $11.3 billion. Lilly also raised its full-year revenue guidance to$45.4 billion-$46.6 billion and earnings per share guidance to$15.10-$15.40 per share. The market responded as if Lilly was selling artificial intell ...